Skip to main content
  • Paul Scherrer Institut PSI
  • PSI Research, Labs & User Services

Digital User Office

  • Digital User Office
  • DE
  • EN
  • FR
Paul Scherrer Institut (PSI)
Suche
Paul Scherrer Institut (PSI)

Hauptnavigation

  • Research at PSIOpen mainmenu item
    • Research Initiatives
    • Research Integrity
    • Scientific Highlights
    • Scientific Events
    • Scientific Career
    • PSI-FELLOW
    • PSI Data Policy
  • Research Divisions and LabsOpen mainmenu item
    • Overview
    • Research with Neutrons and Muons
    • Photon Science
    • Energy and Environment
    • Nuclear Energy and Safety
    • Biology and Chemistry
    • Large Research Facilities
  • Facilities and InstrumentsOpen mainmenu item
    • Overview
    • Large Research Facilities
    • Facilities
    • PSI Facility Newsletter
  • PSI User ServicesOpen mainmenu item
    • User Office
    • Methods at the PSI User Facilities
    • Proposals for beam time
    • Proposal Deadlines
    • Data Analysis Service (PSD)
    • EU support programmes
  • DE
  • EN
  • FR

Digital User Office (mobile)

  • Digital User Office

You are here:

  1. PSI Home
  2. Labs & User Services
  3. BIO
  4. CRS
  5. Roger Schibli

Secondary navigation

Center for Radiopharmaceutical Sciences (CRS)

  • Laboratory Head
  • Project Leader
  • Scientific Highlights
  • Groups
    • Nuclide Chemistry
    • Pharmacology
    • Clinical Drug Supply
    • Radionuclide-Production and Maintenance
    • Development of Radionuclides
  • Facilities and Instruments
  • Teaching and Education
  • Publications
  • Team / Contact

Prof. Dr. Roger Schibli

Prof. Roger Schibli

Head of the Center for Radiopharmaceutical Sciences ETH-PSI-USZ

Paul Scherrer Institute
Forschungsstrasse 111
5232 Villigen PSI
Switzerland
Telephone
+41 56 310 28 37
Email
roger.schibli@psi.ch

Curriculum Vitae
Prof. Roger Schibli is an Associate Professor in the Department of Chemistry and Applied Biosciences (ETH Zurich) since 2010, and Head of the Center for Radiopharmaceutical Science (CRS), a joint endeavor between the ETH Zurich, the Paul Scherrer Institute and the University Hospital Zurich. Prof. Schibli studied Chemistry at the University of Basel, Switzerland and performed his doctoral thesis under the supervision of Prof. Thomas Kaden. After his graduation, he spent two years at the University of Missouri-Columbia, MO as a post-doctoral fellow. He was appointed Assistant Professor (tenure track) for Therapeutics Technologies at the Institute of Pharmaceutical Sciences (ETH Zurich) in 2004 and was tenured in 2009.
Prof. Schibli's research interestscover targeted tumor diagnosis and therapy using radiolabeled compounds. Apart from the chemical modification and radioactive labeling of molecules, his group emphasizes on the biological and pharmacological characterization and optimization of the radioactive compounds including non-invasive PET and SPET imaging. New, medically relevant radionuclides for his pre-clinical and clinical studies are produced at the cyclotron and neutron facilities of the ETH and the Paul Scherrer Institute.
 

Sidebar

Contact

ETH
Prof. Dr. Roger Schibli
Swiss Federal Institute of Technology Zurich
Radiopharmaceutical Sciences
ETH Zurich


Contact

University Hospital Zurich
Radiopharmacy
USZ
top

Footer

Paul Scherrer Institut

Forschungsstrasse 111
5232 Villigen PSI
Switzerland

Telephone: +41 56 310 21 11
Telefax: +41 56 310 21 99

How to find us
Contact form

Visitor Centre psi forum
School Lab iLab (in German)
Center for Proton Therapy
PSI Education Centre
PSI Guest House
PSI Gastronomie (in German)

 

Service & Support

  • Phone Book/People Search
  • User Office
  • Accelerator Status
  • PSI Publications
  • Suppliers
  • E-Billing
  • Computing
  • Safety (in German)

Career

  • Working at PSI
  • Job Opportunities
  • Training and further education
  • Vocational Training (in German)
  • PSI Education Center

For the media

  • PSI in brief
  • Facts and Figures
  • Media Contact
  • Media Releases
  • Social Media Newsroom

Follow us: Twitter (in English) LinkedIn Youtube Issuu RSS

Footer legal

  • Imprint
  • Terms and Conditions
  • Editors' login